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Abstract
Primary cilia are sensory organelles involved in regulation of cellular signaling. Cilia loss 
is frequently observed in tumors; yet, the responsible mechanisms and consequences 
for tumorigenesis remain unclear. We demonstrate that cilia structure and function is 
disrupted in human pheochromocytomas – endocrine tumors of the adrenal medulla. 
This is concomitant with transcriptional changes within cilia-mediated signaling pathways 
that are associated with tumorigenesis generally and pheochromocytomas specifically. 
Importantly, cilia loss was most dramatic in patients with germline mutations in the 
pseudohypoxia-linked genes SDHx and VHL. Using a pheochromocytoma cell line derived 
from rat, we show that hypoxia and oncometabolite-induced pseudohypoxia are key 
drivers of cilia loss and identify that this is dependent on activation of an Aurora-A/
HDAC6 cilia resorption pathway. We also show cilia loss drives dramatic transcriptional 
changes associated with proliferation and tumorigenesis. Our data provide evidence 
for primary cilia dysfunction contributing to pathogenesis of pheochromocytoma by a 
hypoxic/pseudohypoxic mechanism and implicates oncometabolites as ciliary regulators. 
This is important as pheochromocytomas can cause mortality by mechanisms including 
catecholamine production and malignant transformation, while hypoxia is a general 
feature of solid tumors. Moreover, pseudohypoxia-induced cilia resorption can be 
pharmacologically inhibited, suggesting potential for therapeutic intervention.
Introduction
Pheochromocytomas (PCCs) are neuroendocrine tumors 
that originate from chromaffin cells of the adrenal medulla 
or autonomic nervous system, where they are termed 
paragangliomas (PGLs). The majority of the morbidity 
associated with PCC/PGLs is consequent upon their 
production of catecholamines, leading to severe, life-
threatening hypertension, but they may also cause local mass 
effect and have the potential for metastatic spread (Fishbein 
& Nathanson 2012, Burnichon et al. 2016). Understanding 
of the pathogenesis of PCC/PGLs is incomplete, with limited 
ability to predict malignant potential and at present the 
response to conventional cancer therapies is disappointing.
Approximately 30% of PCC/PGLs are associated 
with inherited germline mutations in more than 15 
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different susceptibility genes (Dahia 2017). These include 
causative genes for inherited cancer syndromes, where, 
relative to other tumor types, there is a high incidence of 
PCC/PGL. Recent analyses of germline and somatic 
mutations have classified PCC/PGL into four molecularly 
defined groups, including a pseudohypoxia-linked 
subtype (Fishbein et  al. 2017). These pseudohypoxic 
tumors occur due to mutations that impact regulation 
of the hypoxia transcription factors HIF1α and HIF2α. 
This can be through germline or somatic mutation of the 
ubiquitin E3 ligase pVHL (von Hippel–Lindau protein), 
which targets HIFα for degradation by the ubiquitin 
proteasome system (Dannenberg et  al. 2003, Gossage 
et al. 2015, Crespigio et al. 2017). Increased HIF activity 
also results from germline mutation in genes that encode 
the succinate dehydrogenase (SDH) complex subunits 
(SDHA, SDHB, SDHC, SDHD), succinate dehydrogenase 
complex assembly factor 2 (SDHAF2), fumarate hydratase 
(FH) and malate dehydrogenase (MDH2) (Fishbein & 
Nathanson 2012). This is because loss of their function 
leads to accumulation of oncometabolites that inhibit 
pVHL-mediated degradation of HIFα (Selak et al. 2005).
Although pseudohypoxic mechanisms account, at 
least in part, for angiogenesis-facilitated growth, they 
do not, of themselves, satisfactorily explain PCC/PGL 
tumorigenesis. Mutations in the VHL gene are known 
to be important in renal cancers; this includes the 
occurrence of clear cell renal cell carcinoma (ccRCC) as 
part of the inherited cancer syndrome von Hippel–Lindau 
disease, in which VHL is mutated and PCC/PGL can occur 
(Gossage et  al. 2015, Crespigio et  al. 2017). One of the 
hallmark features of ccRCC is the loss of primary cilia 
(Basten et  al. 2013), which act as flow sensors on renal 
epithelial cells. Cilia are cellular organelles that consist of a 
microtubule-based core structure, known as the axoneme, 
which elongates from a basal body and is covered by the 
ciliary membrane. Cilia function as signaling platforms 
involved in the transduction of extracellular stimuli, 
through mechanisms including regulating the spatial 
compartmentalization of signaling components (Berbari 
et  al. 2009, Goetz & Anderson 2010). For example, 
primary cilia are modulators of WNT signaling and have 
an essential role in mammalian hedgehog (Hh) signaling 
(Berbari et al. 2009, Wong et al. 2009, Goetz & Anderson 
2010, Lancaster et al. 2011, Oh & Katsanis 2013).
The coordination of cilia-mediated signaling is 
influenced by the dynamic nature of cilia, which elongate 
and shorten in response to cell cycle stage and other 
stimuli. This requires the process of intraflagellar transport 
(IFT) to traffic ciliary components in both anterograde 
and retrograde directions along axonemal microtubules. 
Cilia are assembled when cells enter stationary phase and 
are normally resorbed prior to cell division. This occurs 
as the basal body, which acts as a nucleation site for the 
growth of axoneme microtubules during ciliogenesis, 
is derived from a mother centriole and is required for 
mitotic spindle pole formation. Importantly, the mother 
centriole has this dual role means that the presence of a 
primary cilium potentially acts as a checkpoint within the 
cell cycle (Izawa et al. 2015). Thus, cilia might oppose cell 
division and proliferation; however, it should be noted 
that there are instances where cilia are present on mitotic 
cells (Goto et al. 2013). Dysregulation of normal restraints 
on cellular proliferation is required for neoplastic 
progression, and it is hypothesized that disruption of a 
ciliary cell cycle checkpoint may promote tumorigenesis 
(Mans et  al. 2008), although ciliopathy patients have 
not been identified as having an increased risk of cancer 
(Johnson & Collis 2016).
Here, we address key questions regarding the loss of 
cilia in tumor cells in the context of PCC/PGLs. These 
include whether cilia loss is correlated with changes in 
cilia-mediated signaling in vivo. We also consider whether 
cilia loss increases cellular proliferation or is a consequence 
of it. We demonstrate that primary cilia loss is a feature of 
PCC/PGL and in particular those that are driven by germline 
mutations in pseudohypoxia-linked genes. This finding is 
consistent with transcriptome-based evidence from PCCs 
for dysregulation of cilia maintenance and cilia-mediated 
signaling pathways. Using a rat PCC-derived cell line 
(PC12), we define the molecular mechanism of primary 
cilia loss, demonstrating that axonemal resorption is 
dependent on both HIF signaling and Aurora-A kinase 
activation. Moreover, loss of primary cilia in PC12, 
induced by ciliary protein knockdown, leads to increased 
proliferation and alterations in expression of genes 
associated with pathways involved in proliferation and 
cancer. We also show that knockdown of pseudohypoxia-
causing PCC/PGL genes and treatment with inhibitors 
that trigger accumulation of oncometabolites result in 
primary cilia loss.
Materials and methods
Tissue sample collection and preparation for 
immunolabeling and RNA extraction
Samples of tumor and adjacent adrenal medulla, where 
available, were collected at the time of adrenalectomy 
(for PCC) or PGL resection (patient recruitment and 
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ethical approval is described in the Supplementary data, 
see section on supplementary data given at the end 
of this article). PCC and normal adrenal medulla were 
differentiated at the time of surgery with subsequent 
pathology analysis. For immunofluorescence, samples 
were fixed in 4% paraformaldehyde, resuspended in 30% 
sucrose and embedded in OCT compound (VWR) prior to 
storage at −80°C. For RNA extraction, tissue samples were 
placed directly into RNAlater (Thermo Fisher Scientific) 
and stored at −20°C. Samples were subsequently 
homogenized in RLT buffer and purified using RNeasy 
Mini Kit (Qiagen).
Cell culture and experimental treatments
Cell lines were cultured and treated with drugs as 
described in Supplementary data. PC-12 Adh (ATCC 
CRL-1721.1) cells were obtained from the American Type 
Culture Collection; for cilia assembly experiments, cells 
were plated and grown in complete media for 24 h prior to 
serum starvation for a further 24 h or otherwise specified. 
For cilia disassembly experiments serum-containing 
media was reintroduced for 24 h after starvation or as 
otherwise specified.
Immunofluorescent detection and quantification of 
primary cilia
The immmunostaining protocols and antibodies used are 
described in Supplementary data. Confocal microscopy 
was performed using an LSM510 or LSM880 laser 
scanning confocal microscope (Zeiss). Quantification 
of cilia incidence and length was performed blinded to 
experimental status. Cilia incidence was defined as the 
number of cells with a cilium (identified by two axonemal 
markers) divided by the number of nuclei in a given field. 
Cilia length was measured from maximum intensity 
projections created from confocal Z-stacks using Zen 
(Zeiss) and ImageJ (NIH) software. The surpass module 
of Imaris 7.1 image processing and analysis software 
(Bitplane) was used to surface render 3D images.
siRNA-mediated knockdown
PC12 cells were transfected with either targeted or non-
targeted control siRNAs (Silencer Select, Ambion) using 
Lipofectamine 3000 (Thermo Fisher Scientific), according 
to the manufacturer’s instructions. For knockdown of 
VHL, SDHB and FH, IFT88 and Cep164 – two distinct 
siRNAs each targeting distinct exons – were used at a total 
concentration of 30 nM (sequences available on request).
RNA-sequence data and pathway analyses
RNA extraction and sequencing is described in 
Supplementary data. All analyses were conducted in the 
R statistical environment, version 3.4.0, using software 
from the Bioconductor repository (Huber et  al. 2015). 
Functional analysis of differential gene expression between 
control and Ift88-knockdown cells was performed using 
Ingenuity Pathways Analysis (IPA; Ingenuity Systems), 
using all genes with log fold change ≥2 and q-value was 
<0.01, as input. For all gene set enrichment analyses, a 
right-tailed Fisher’s exact test was used to calculate a 
pathway P-value determining the probability that each 
biological function assigned to that data set was due to 
chance alone. All enrichment scores were calculated in 
IPA using all transcripts that passed QC as the background 
data set. For more details of transcriptome and pathway 
analyses, see our supplemental R Markdown document 
(https://github.com/C4TB/markdown-chapple_pcc).
Results
The incidence and length of primary cilia is reduced 
in PCCs relative to adjacent normal adrenal medulla
We collected paired tissue samples from PCCs and 
adjacent macroscopically normal adrenal medulla from 25 
patients who underwent adrenalectomy. Two individuals 
had bilateral disease giving a total of 27 paired samples 
(Table  1 and Supplementary Table  1). The tissues were 
immunostained for the axonemal proteins acetylated 
α-tubulin and ADP-ribosylation factor-like protein 13B 
(Arl13b) and analyzed for the incidence of cells with a 
primary cilium (Fig. 1A). This showed that the occurrence 
of a primary cilium was lower (P = 4.74 × 10−11) in PCCs 
(3.06 ± 0.14% of cells) compared to adrenal medulla 
(8.42 ± 0.03% of cells) (Fig. 1B). The length of the ciliary 
axoneme was also reduced (P = 8.24 × 10−11) in PCC cells 
that still had cilia (1.48 ± 0.34 μm) relative to cells in 
adjacent adrenal medulla (2.02 ± 0.39 μm) (Fig.  1C). 
The incidence and length of primary cilia measured in 
individuals correlated in both PCCs and adjacent adrenal 
medulla, although this relationship was stronger in PCCs 
than adjacent adrenal medulla (PCC P < 0.001, r2 = 0.66; 
adrenal P = 0.001, r2 = 0.36) (Fig.  1D). We also observed 
that in every instance cilia incidence was lower in the 
PCC than its adjacent adrenal medulla (Supplementary 
Fig.  1A). This was also the case for cilia length in all 
but one of the paired samples (Supplementary Fig.  1B). 
Together, these data established that loss of primary cilia 
is a feature of PCC.
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It has previously been reported that the tumor 
suppressor pVHL plays a role in ciliogenesis (Schermer 
et  al. 2006). Thus, we next compared cilia loss and 
length reduction in PCC from patients with germline 
mutations in VHL compared to those without. We found 
that both cilia incidence (1.40 ± 0.01% vs 3.43 ± 0.02) and 
length (1.15 ± 0.35 μm vs 1.58 ± 0.31 μm) were reduced 
in VHL-PCCs compared to non-VHL-PCCs (P = 0.010 for 
incidence, P = 0.010 for length) (Fig. 1E and F). There was 
no significant difference in either cilia incidence or length 
in adjacent adrenal medulla from VHL and non-VHL 
patients (Fig. 1E and F). This suggests that cilia loss and 
shortening in VHL-PCCs occurs during tumorigenesis and 
is not a pre-existing/pre-malignant feature.
In order to further evaluate whether this finding 
was specific to VHL or a feature of other pseudohypoxic 
PCCs, we extended our analysis to include an additional 
20 tumors from 15 patients from whom a paired 
adrenal sample was unavailable (total 47 PCC/PGL 
from 40 patients; Table 1 and Supplementary Table 2). 
We compared PCC/PGLs from patients with germline 
mutations in VHL, to tumors from patients with 
germline mutations in SDHx and those without a known 
germline mutation in a pseudohypoxia-linked gene. 
Cilia incidence was reduced in PCC/PGLs from patients 
with germline mutations in VHL (P = 0.0007) and 
SDHx (P = 0.0103 for incidence), relative to PCC/PGLs 
from patients that were not of a pseudohypoxia-linked 
subtype (Fig.  1G). Cilia length was also reduced in 
VHL- and SDHx-PCC/PGLs relative to the non-
pseudohypoxia tumors, although this was only 
significant for VHL (P = 0.0013) (Fig. 1H).
We also examined if there was any correlation between 
cilia loss and clinical disease parameters in patients with 
PCC/PGL. Patients under 18 years of age at the time of 
surgery had tumor cells with fewer and shorter cilia than 
patients who were over the age of 18 years (Supplementary 
Fig. 1C and D), suggesting an association between cilia loss 
Table 1 Clinical details – summary table.
Paired Unpaired All
Samples (n) 27 20 47
Patients (n) 25 15 40
Sex
 Male; n (%) 12 (48) 7 (47) 19 (47.5)
 Female; n (%) 13 (52) 8 (53) 21 (52.5)
Age (years)
 Mean ± s.e.m. 46.8 ± 4.0 46.2 ± 3.4 46.6 ± 2.8
 Range 12–78 15–68 12–78
Size (mm)
 Mean ± s.e.m. 49 ± 4 47 ± 7 48 ± 4
 Range 8–87 13–120 8–120
Location
 Adrenal (%) 27 (100) 7 (35) 34 (72)
 PGL (%) 0 (0) 13 (65) 13 (28)
Mode of diagnosis
 Symptomatic (%) 9 (33) 9 (45) 18 (38)
 Incidental (%) 14 (52) 7 (35) 21 (45)
 Screening (%) 4 (15) 4 (20) 8 (17)
Germline mutation (patients) (%) 5 (25) 8 (53) 13 (33.5)
 SDHA 0 1 1
 SDHB 1 4 5
 VHL 3 2 5
 MEN2 1 1 2
Germline mutation (tumors) (%) 7 (26) 13 (65) 20 (42.6)
 SDHA 0 3 3
 SDHB 1 5 6
 VHL 5 4 9
 MEN2 1 1 2
Incidental, diagnosis due to investigation for another unrelated condition; MEN2, multiple endocrine neoplasia 2; mode of diagnosis – symptomatic, 
diagnosis due to symptoms or signs of catecholamine excess leading to diagnosis; PGL, paraganglioma; screening, diagnosis during a screening 
program in individuals with known pheo/PGL predisposition; SDH, succinate dehydrogenase; s.e.m., standard error of the mean; VHL, von  
Hippel–Lindau.
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Figure 1
Primary cilia incidence and length is reduced in PCCs relative to adjacent adrenal medulla. (A) Maximum intensity projections (MIP) of confocal Z-stacks of 
PCC and adjacent adrenal medulla. Tissue sections were processed for dual-immunofluorescent detection of the ciliary markers acetylated α-tubulin 
(green) and Arl13b (red). They were then counterstained with DAPI (blue) to detect nuclei. A single confocal section from the area demarked by the 
dashed box is shown zoomed (XY zoom). Individual cilia, indicated by arrows, are further enlarged in insets 1–6 and are shown as surface rendered 3D 
images in the panels on the right. Scale bars = 10 µm. (B) Quantification of primary cilium incidence in 27 paired PCC and adjacent adrenal medulla tissue 
samples. (C) Quantification of axoneme length (from confocal Z-stacks) from cells that had a primary cilium in PCC and adjacent adrenal medulla. (D) Cilia 
incidence and length correlate in both PCCs and adjacent adrenal medulla, with a more significant relationship in tumor than normal tissue. (E and F) 
Cilia incidence and length in 27 paired PCCs and adrenal medulla samples comparing individuals with (n = 5) and without (n = 22) germline mutations in 
VHL. (G and H) Cilia incidence and length in 47 PCC/PGL comparing those with a germline mutations in VHL (n = 9), to tumors from patients with germline 
mutations in SDHx (n = 9) and those without a known germline mutation in a pseudohypoxia-linked gene (Con, n = 29). (I) Cilia incidence in 33 PCC where 
more or less than 3% of cells labeled positively for Ki67. The number of cilia and nuclei were counted in 15 randomly selected fields for each sample. 
Mean axonemal length was quantified from at least 50 ciliated cells for each sample. Error bars indicate s.d. Statistical tests: t-test (B, C, E, F and I), ANOVA 
(G and H), linear regression (D). *P < 0.05, **P < 0.01, ***P < 0.001.
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and age (at time of surgery). As the presence of a primary 
cilium is potentially a checkpoint for cell division, we next 
tested if cilia loss correlated with cellular proliferation in 
PCC/PGLs. This was by quantifying the percentage of cells 
that labeled positively for Ki67 (quantified by routine 
clinical immunohistochemistry), a marker of proliferative 
activity that has previously been correlated with malignant 
potential in PCCs (Clarke et al. 1998, Kimura et al. 2014). 
Cilia incidence was reduced in PCCs/PGLs that had a 
Ki67 index of 3% or higher (P = 0.0159) compared to PCC 
/PGLs with a lower Ki67 index (P = 0.0159) (Fig. 1I). These 
data indicate that degree of cilia loss is linked to clinical 
parameters in PCC/PGLs.
Dysregulation of cilia-mediated signaling  
pathways in PCCs
We hypothesized that the reduced incidence and length 
of primary cilia in PCCs, relative to adrenal medulla, 
may result in alterations in cilia-mediated signaling. 
This was examined using RNA-Seq transcriptome 
analysis of 12 PCCs and adjacent adrenal medulla 
(Supplementary Table  1) to identify differentially 
expressed cilia-linked gene networks. We performed 
principal component analysis (PCA) on the filtered, 
normalized and transformed count matrix to explore 
the data’s latent structure (Fig.  2A). This revealed that 
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Figure 2
Changes in expression of cilia-linked genes in the transcriptomes of PCCs relative to adrenal medulla. (A) Principal component analysis (PCA) of RNA-seq 
expression data from 12 paired PCC and adjacent adrenal medulla tissue samples. (B) Volcano plot showing log10 FDR-adjusted q values versus log2 fold 
change between PCC and adjacent adrenal medulla. The vertical and horizontal dotted lines indicate 2× or −2× fold change and q = 0.01, respectively.  
(C) Heat map and hierarchical clustering depiction of all differentially expressed module eigengenes, from a collection of 32 gene sets known to be 
associated with cilia structure and cilia-mediated signaling, that are altered between PCCs and adjacent adrenal medulla. (D) Heat map and hierarchical 
clustering depiction of differentially expressed genes in the GO_NONMOTILE_PRIMARY_CILIUM pathway, comparing PCC and adjacent adrenal medulla 
samples. (E, F and G) Heat map and hierarchical clustering depictions of differentially expressed genes in three cilia-associated signaling pathways that 
are altered in PCCs relative to adjacent adrenal medulla: (E) HALLMARK_HEDGEHOG_SIGNALING; (F) BIOCARTA_WNT_PATHWAY; (G) GO_NEGATIVE_
REGULATION_OF_NOTCH_SIGNALING_PATHWAY. Numbers shown at the bottom of the heat maps correspond to the sample IDs shown in the PCA (but 
are not prefixed with ‘H’).
https://doi.org/10.1530/ERC-18-0134
https://erc.bioscientifica.com © 2019 The authors
Printed in Great Britain
Published by Bioscientifica Ltd.
This work is licensed under a Creative Commons 
Attribution 4.0 International License.
Downloaded from Bioscientifica.com at 11/08/2019 12:42:39PM
via free access
171S M O’Toole et al. Cilia loss in 
pheochromocytoma
26:1Endocrine-Related 
Cancer
principal component 1, which accounts for nearly 40% 
of all variation in the counts, separated the PCC samples 
from adjacent adrenal medulla. PCC samples were spread 
along principal component 2, which accounts for over 
10% of data variance, indicating a heterogeneity in this 
group that is absent in adjacent adrenal medulla, where 
samples cluster together more closely.
Our unsupervised analysis suggested a strong 
transcriptomic signal differentiating tumor and adrenal 
medulla samples. To quantify this and identify relevant 
biomarkers, we conducted differential expression 
analysis using the DESeq2 software package (Love et  al. 
2014). We defined a gene as differentially expressed if its 
absolute log fold change ≥2 and its q-value was ≤0.01, 
imposing a false discovery rate of 1%. This strict threshold 
ensured high specificity. Overall, 1839 genes met these 
criteria, representing some 8% of the transcriptome after 
filtering (Fig. 2B).
To test if cilia function was altered in PCC relative 
to adjacent adrenal medulla, we curated a collection of 
32 gene sets known to be associated with cilia structure 
and cilia-mediated signaling. We found considerable 
enrichment among these pathways (14 out of 32 at 
q ≤ 0.1). Eigengenes for all modules are depicted in Fig. 2C. 
Altered gene modules included those associated with cilia 
structure. For example, the GO_NONMOTILE_PRIMARY_
CILIUM module showed altered expression in PCC 
tissue relative to adrenal medulla (q = 0.0519) (Fig.  2D), 
suggesting changes in gene expression may contribute 
to cilia loss in PCCs. We also observed changes in the 
Aurora-A Gene module (q = 0.2365), which is of interest as 
activation of Aurora-A pathway plays a role in regulation 
of cilia disassemble.
We also identified that gene modules associated 
with Hedgehog, Wnt and NOTCH signaling were 
altered between PCCs and adrenal medulla e.g. 
HALLMARK_HEDGEHOG_SIGNALING (q = 1.66 × 10−7), 
BIOCARTA_WNT_PATHWAY (q = 0.0519) and GO_
NEGATIVE_REGULATION_OF_NOTCH_SIGNALING_
PATHWAY (q = 1.58 × 10−6). Analyses of these gene modules 
revealed significant upregulation and downregulation of 
individual genes (absolute log fold change ≥2, q ≤ 0.01), 
while hierarchical clustering analyses separately grouped 
tumor and adrenal medulla samples in each of these 
pathways, with the exception of one medulla sample 
(H21) in the Hedgehog and Notch pathways, and two 
tumor samples (H10 and H22) in the Wnt pathway 
(Fig. 2D, E, F and G). These data are consistent with cilia-
mediated signaling pathways being disrupted in PCC, but 
could also be explained by other potential mechanisms.
Disruption of primary cilia function in the  
PCC-derived PC12 cell line promotes proliferation  
and alters expression of tumorigenesis-linked 
gene networks
It is not fully resolved whether cilia loss is a driver or 
consequence of tumorigenesis. To address this question, 
in the context of PCC, we first established that PCC-
derived cultured cell lines are able to form primary cilia. 
This was confirmed in the rat tumor-derived PC12 cell 
line, with cilia incidence and length increasing after serum 
starvation, such that 55.4 ± 5.98% of cells had a detectable 
cilium with a mean axonemal length of 2.17 ± 0.69 μm after 
24 h (Fig. 3A, B, C and Supplementary Fig. 2A, B, C). Cilia 
were also present and responsive to serum starvation in 
two mouse PCC cell lines, MPC and MTT (Supplementary 
Fig. 2D, E and F). It should be noted that PC12 cells do not 
express the Myc dimerization partner MAX, while MPC 
and MTT lines were derived from the neurofibromatosis 
type 1 (NF1)-knockout mouse (Hopewell & Ziff 1995, 
Burnichon et al. 2012, Korpershoek et al. 2012).
We next disrupted cilia function in PC12 cells through 
siRNA-mediated knockdown of either the IFT88, a central 
component of the intraflagellar transport complex (Pazour 
et al. 2000), or Cep164, which plays a role in microtubule 
organization and/or maintenance for the formation of 
cilia (Graser et al. 2007). IFT88 knockdown was confirmed 
by immunoblot (Supplementary Fig.  3A and B), while 
knockdown of Cep164 was confirmed at the level of 
transcript (Supplementary Fig. 3C). Knockdown cells were 
then immunolabeled to detect cilia and stained with the 
proliferation marker Ki67 (Fig. 3D). Quantitative analysis 
confirmed, compared to control cells transfected with a 
non-targeting siRNA, that cilia incidence was reduced 
in both IFT88 (P = 0.02577) and Cep 164-knockdown 
cells (P = 0.0.00222) (Fig. 3E and H). Cilia length was also 
reduced in both instances (Supplementary Fig.  3D and 
E). Moreover, the percentage of Ki67-positive cells was 
increased after both IFT88 knockdown (P = 4.35 × 10−12) 
and Cep164 knockdown (P = 0.03937) (Fig.  3F and I). 
Increased proliferation of IFT88 and Cep164 knockdown 
PC12 cell, relative to controls, was further confirmed 
by quantification of cell numbers 48 h after siRNA 
transfection (Fig. 3G and J).
To further understand how disruption of cilia 
function impacts on cellular proliferation, we compared 
the transcriptomes of IFT88 knockdown and control 
cells (transfected with non-targeting siRNA) by RNA-Seq. 
Reads were pseudo-aligned (using the same pipeline 
as described for PCC and adrenal medulla) and 
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Figure 3
Loss of primary cilia in PC12 cells promotes proliferation and alters gene expression. (A) Confocal images of PC12 cells cultured in the absence of serum 
for between 0 and 72 h. Cells were immunolabeled with anti-acetylated α-tubulin (green) and anti-Arl13b (red) for detection of primary cilia. Nuclei were 
stained with DAPI (blue). Cilia are indicated by arrows, or arrowheads where they are also shown zoomed in the insets. Scale bars = 10µm. (B and C) 
Quantification of primary cilia incidence (B) and axonemal length (C) under conditions of serum starvation. (D) Confocal images of PC12 cells cultured for 
48 h after transfection with siRNA targeting IFT88, Cep164, or non-targeting control siRNAs (Con). Cells were immunolabeled to detect cilia (Arl13b, green) 
and the proliferation marker Ki67 (red). Nuclei were stained with DAPI (blue). Cilia are indicated by arrows and Ki67 positive cells by arrowheads. Scale 
bars = 10 µm. (E, F, G and H) Quantification of primary cilia incidence (E), the percentage of Ki67 positive cells (F), and relative cell numbers (G), 48 h after 
transfection with siRNA targeting IFT88. (H, I and J) Quantification of primary cilia incidence (H), the percentage of Ki67 positive cells (I) and relative cell 
numbers (J), 48 h after transfection with siRNA targeting Cep164. Cilia and Ki67 scoring were performed in ten randomly selected fields for each 
experimental condition in three biological replicates. Mean axonemal length was quantified from at least 50 ciliated cells for each experimental 
condition. Cell counting was performed on six samples from three biological replicates. Error bars indicate 2× s.e.m. In box and whisker plots, the box 
represents median, upper and lower quartiles and the whiskers the 10th and 90th centiles. Statistical tests: ANOVA (B and C), t-test (E, F and G). *P < 0.05, 
**P < 0.01, ***P < 0.001. (K) Gene Ontology (GO) analysis of the transcriptome of PC12 cells transfected with siRNA targeting IFT88 or non-targeting 
control siRNAs, showing the top-ranking altered biological processes identified by Ingenuity Pathways Analysis. q values are depicted in red (E = 10 to the 
power of the following number). (L and M) Heat map and hierarchical clustering depictions of differentially expressed genes in altered pathways with the 
GO terms cell death (L), tumorigenesis of tissues (M) and cell proliferation of tumor cells (N). Numbers shown at the bottom of the heat maps correspond 
to sample IDs shown in Supplementary Fig. 3.
https://doi.org/10.1530/ERC-18-0134
https://erc.bioscientifica.com © 2019 The authors
Printed in Great Britain
Published by Bioscientifica Ltd.
This work is licensed under a Creative Commons 
Attribution 4.0 International License.
Downloaded from Bioscientifica.com at 11/08/2019 12:42:39PM
via free access
173S M O’Toole et al. Cilia loss in 
pheochromocytoma
26:1Endocrine-Related 
Cancer
PCA performed. PC1 separated IFT88 knockdown and 
control cells, accounting for over 30% of the variation 
in the counts (Supplementary Fig.  3F). We found 662 
genes differentially expressed at q ≤ 0.01 (Supplementary 
Fig.  3G), representing some 6% of the transcriptome 
after filtering. Ingenuity pathways analysis was then 
used to identify statistically significant functions of the 
differentially regulated genes. This gene ontology (GO) 
analysis revealed that the top ten biological processes of 
these genes were related to cell death, cell proliferation 
and tumorigenesis. Moreover, activation z-scores 
suggested that cell death pathways were inhibited while 
proliferation and tumorigenesis pathways were induced 
(Fig.  3K). Hierarchical cluster analysis of gene modules 
described by the GO terms ‘cell death’, ‘tumorigenesis 
of tissues’, and ‘cell proliferation of tumor cells’ clearly 
separated IFT88-knockdown samples from controls 
(Fig.  3L, M and N). These data suggest that cilia loss 
promotes proliferation of PC12 cells.
PC12 cells resorb primary cilia under 
hypoxic conditions
Primary cilia incidence was most reduced in tumors 
with germline mutations in VHL and SDHx (Fig.  1G). 
This suggested that hypoxic signaling may be a driver 
of cilia loss. To test this hypothesis, we exposed ciliated 
PC12 cells (grown in serum-free conditions for 24 h) to 
normal cell culture oxygen levels (21% O2) and hypoxic 
conditions (1% O2). Cells were then immunolabeled 
to detect cilia. Subsequent confocal imaging and 
quantitative analysis demonstrated that culture of 
ciliated PC12 cells in 1% O2 caused a reduction in 
cilia incidence (P = 3.75 × 10−15) and length (P = 0.0106) 
(Fig. 4A, B and C). This cilia resorption was shown to be 
transient, with PC12 cells able to reform primary cilia 
within 24 h of return to 21% O2 (Fig. 4B and C). We also 
looked at the effect of oxygen levels on ciliogenesis. Cilia 
formation, induced by culture in serum-free conditions, 
was compared in cells maintained under normoxic (21% 
O2) and hypoxic conditions (1% O2). Lowered oxygen 
levels again resulted in cells having a reduction in 
cilia incidence (P = 1.27 × 10−5) and length (P = 0.0075) 
(Fig.  4D and E). To further confirm cilia loss occurred 
in PCC-derived cell lines cultured under hypoxic 
conditions, we immunolabeled MPC and MTT cells to 
detect cilia. In MPC and MTT cell lines, primary cilia 
incidence (MPC P = 0.002; MTT P = 0.0351) and length 
(MPC P = 1.00 × 10−15; MTT P = 0.0001) was reduced after 
transfer to 1% O2 for 24 h (Supplementary Fig. 4).
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Figure 4
Primary cilia are lost from PC12 cells when oxygen levels are reduced.  
(A) Confocal images of PC12 cells cultured in 21% or 1% oxygen for 24 h, prior 
to return to 21% oxygen for 4, 8, 24 or 48 h before processing for the 
detection of primary cilia as in Fig. 3A. Scale bars = 10 µm. (B and C) 
Quantification of primary cilia incidence (B) and axonemal length (C) after 
24 hours of culture in 21% and 1% oxygen and subsequent recovery in 21% 
oxygen. (D and E) Comparison of primary cilia incidence (D) and axonemal 
length (E) upon serum starvation after culture in 21% or 1% oxygen. (F and G) 
Quantification of primary cilia incidence (F) and axonemal length (G) after 
24 h of culture in 1% oxygen in the presence of the HIFα inhibitor FM19G11 
or vehicle only control. (H and I) Quantification of primary cilia incidence (H) 
and axonemal length (I) after 24 h of culture in 1% oxygen in cells transfected 
with non-targeting control siRNAs or siRNA targeting HIF1α. (J and K) 
Quantification of primary cilia incidence (J) and axonemal length (K) after 24 h 
of culture in 1% oxygen in the presence of the inhibitors trichostatin A (TSA), 
tubacin, PHA-680632 or vehicle only control. Cilia scoring was performed in 
ten randomly selected fields for each experimental condition in three 
biological replicates. Mean axonemal length was quantified from at least 50 
ciliated cells for each experimental condition. Error bars indicate 2× s.e.m. Box 
and whisker plots are as in Fig. 3. Statistical tests: ANOVA. *P < 0.05, 
**P < 0.01, ***P < 0.001.
https://doi.org/10.1530/ERC-18-0134
https://erc.bioscientifica.com © 2019 The authors
Printed in Great Britain
Published by Bioscientifica Ltd.
This work is licensed under a Creative Commons 
Attribution 4.0 International License.
Downloaded from Bioscientifica.com at 11/08/2019 12:42:39PM
via free access
174S M O’Toole et al. Cilia loss in 
pheochromocytoma
26:1Endocrine-Related 
Cancer
To investigate if the loss of primary cilia under hypoxic 
conditions was dependent on HIF-mediated signaling, 
we added the HIFα inhibitor FM19G11 (Moreno-Manzano 
et  al. 2010) to culture media prior to transfer of cells 
to 1% O2. Compared to vehicle-only-treated control 
cells, FM19G11 prevented hypoxia-induced cilia loss 
(P = 8.68 × 10−5 for incidence, P = 7.08 × 10−6 for length) 
(Fig. 4F, G and Supplementary Fig. 4D). We further tested 
a role for HIF1α signaling in hypoxia-induced cilia loss by 
targeting with siRNA. This showed that HIF1α knockdown 
was able to rescue cilia loss in PC12 cells cultured in 1% 
O2 (Fig. 4H, I and Supplementary Fig. 4E, F). To further 
understand the mechanism of hypoxia-induced cilia loss, 
we next tested for involvement of the Aurora-A kinase 
/histone deacetylase 6 (HDAC6) pathway. Activation 
of Aurora-A has been shown to cause phosphorylation 
of HDAC6, which deacetylates ciliary tubulin and 
destabilizes the axonemal microtubules (Pugacheva et al. 
2007). Inhibition of Aurora-A, with the specific inhibitor 
PHA-680632, prevented cilia loss (P = 1.85 × 10−7) and 
shortening (P = 2.94 × 10−6) in cells exposed to 1% O2 
(Fig. 4J, K and Supplementary Fig. 4D). Hypoxia-induced 
cilia loss was also inhibited by the mammalian class I and 
II HDAC inhibitor trichostatin A (TSA) (P = 3.22 × 10−8 
for incidence, P = 3.29 × 10−8 for length) and the selective 
HDAC6 inhibitor tubacin (P = 1.11 × 10−4 for incidence, 
P = 0.0487 for length) (Fig.  4J, K and Supplementary 
Fig.  4D). These data suggest that reduced oxygen levels 
lead to cilia resorption in PC12 cells by a mechanism that 
includes HIF signaling and activation of the Aurora-A 
kinase/HDAC6 pathway.
In addition to degradation of HIF, pVHL stabilizes 
microtubules and plays a role in cilia maintenance. It 
is reported that loss of pVHL alone does not affect cilia 
structure but may sensitize cells to lose pre-established 
cilia (Thoma et  al. 2007). pVHL has been shown to 
localize to the ciliary axoneme, and this was also the 
case in PC12 cells (Supplementary Fig.  4G). We thus 
investigated if activation of hypoxic signaling affected 
localization of pVHL by quantifying levels of the protein 
in the axoneme. Ciliary axonemes were detected by 
immunolabeling for acetylated tubulin and levels 
of pVHL that localized within the region of the cilia 
determined by analyses of fluorescent intensity. This 
showed that pVHL levels were reduced (P = 0.0234) in 
the cilium of cells maintained at 1% O2 relative to cells 
maintained at 21% O2 (Supplementary Fig.  4H). Thus, 
activation of hypoxic signaling may also destabilize 
cilia through a mechanism where pVHL is reduced in 
the ciliary axoneme.
Pseudohypoxia in PC12 cells results in primary cilia 
loss and shortening
Under normoxic conditions HIFα is hydroxylated at 
conserved proline residues by HIF prolyl-hydroxylases 
(HIF-PHDs). This leads to recognition of HIFα by 
VHL, facilitating their ubiquitination and subsequent 
proteasomal degradation. Thus, direct inactivation of 
either HIF-PHDs or VHL can result in persistence of HIFα 
and transcription of HIF target genes even in the presence 
of oxygen – pseudohypoxia. Moreover, succinate, which 
accumulates as a result of loss of SDH function, inhibits 
HIF-PHDs, again resulting in pseudohypoxia (Fig. 5A). To 
establish if pseudohypoxia impacted primary cilia, we 
firstly targeted HIF-PHs by treating PC12 cells with the 
inhibitor dimethyloxalylglycine, N-(methoxyoxoacetyl)-
glycine methyl ester (DMOG). This resulted in reduced 
cilia incidence (P = 3.86 × 10−11) and length (P = 8.00 × 10−14) 
(Fig.  5B, C and Supplementary Fig.  5A). We next tested 
if drivers of the pseudohypoxic PCC/PGL phenotype 
resulted in cilia loss. For SDHB, siRNA-mediated 
knockdown (Supplementary Fig. 5B, C and D) again leads 
to a reduction in cilia incidence (P = 1.20 × 10−8) and length 
(P = 0.00124) (Fig.  5D and E). Cilia loss also occurred in 
the presence of malonate, which competes with succinate 
for active sites of SDH (Fig.  5F, G and Supplementary 
Fig. 5E). Malonate inhibition of SDH can be reversed by 
pharmacologically elevating intracellular α-ketoglutarate 
(MacKenzie et al. 2007). Consistent with this, we observed 
that addition of α-ketoglutarate to PC12 cells rescued 
the cilia loss phenotype observed in cells treated with 
malonate alone (Fig.  5H, I and Supplementary Fig.  5E). 
Similar to succinate, accumulation of fumarate, another 
citric acid cycle intermediate, inhibits HIF-PHDs (this is 
also linked to disease as germline mutations in FH cause 
PCC/PGL). We inhibited FH using the cell-permeable 
derivative of fumarate, monomethyl fumarate. This again 
resulted in the reduction in cilia incidence (P = 1.67 × 10−5) 
and length (P = 2.28 × 10−17) (Fig. 5J, K and Supplementary 
Fig.  5F). The same pattern of reduced cilia incidence 
(P = 4.11 × 10−6) and length (P = 5.75 × 10−19) was observed 
when siRNA-mediated knockdown of FH (Supplementary 
Fig. 5G, H and I) was performed (Fig. 5L and M).
Finally, we investigated the effect of siRNA-mediated 
knockdown of VHL (Supplementary Fig. 5J, K and L) on 
primary cilia. Quantification of cilia incidence and length 
showed that VHL knockdown resulted in fewer cells 
exhibiting a cilium (P = 6.93 × 10−13) and that mean cilia 
length was decreased (P = 8.12 × 10−14) (Fig.  5N and O). 
In summary, these data show cilia loss was induced 
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Figure 5
Inducers of pseudohypoxia cause primary cilia loss and shortening in PC12 cells. (A) Schematic showing PCC linked enzymes and inhibitors used to block 
their action. (B and C) Quantification of primary cilia incidence (B) and axonemal length (C) after 24 h of culture in the presence or absence of DMOG. (D 
and E) Quantification of primary cilia incidence (D) and axonemal length (E) 48 h after transfection with siRNAs targeting SDHB or non-targeting control 
siRNAs (Con). (F and G) Quantification of primary cilia incidence (F) and axonemal length (G) after 24 h of culture in the presence or absence of malonate. 
(H and I) Quantification of primary cilia incidence (H) and axonemal length (I) after 24 h of culture in the presence or absence of malonate (0.1 mM), with 
or without α-ketoglutarate (α-KG). (J and K) Quantification of primary cilia incidence (J) and axonemal length (K) after 24 h of culture in the presence or 
absence of monomethyl fumarate (MMF). (L, M, N and O) Quantification of primary cilia incidence (L and N) and axonemal length (M and O) 48 h after 
transfection with siRNAs targeting FH (L and M) or VHL (N and O) compared to non-targeting control siRNAs (Con). (P and Q) Quantification of the 
percentage of Ki67 positive cells (P) and of relative cell numbers (Q), 48 h after transfection with siRNAs targeting SDHB, VHL or control siRNAs. Cilia and 
Ki67 scoring was performed in ten randomly selected fields for each experimental condition in three biological replicates. Mean axonemal length was 
quantified from at least 50 ciliated cells for each experimental condition. Cell counting was performed on six samples from three biological replicates. 
Error bars indicate 2× s.e.m. Box and whisker plots are as in Fig. 3. Statistical tests: ANOVA (B, C, F, G, H, I, J, K, P, Q), t-test (D, E, L, M, N, O). *P < 0.05, 
**P < 0.01, ***P < 0.001.
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by a number of different conditions that impair HIFα 
degradation, including those that lead to accumulation 
of oncometabolites. Importantly, knockdown of Sdhb 
and Vhl also resulted in increased Ki67 labeling and 
cell number, relative to control cells transfected with a 
non-targeting siRNA (Fig.  5P and Q). This is consistent 
with pseudohypoxia-induced cilia loss correlating with 
increased cellular proliferation.
Inhibition of both the Aurora-A/HDAC6 cilia 
resorption pathways and of hypoxic signaling 
prevents cilia loss in SDHB and VHL-knockdown cells
To understand why cilia incidence and length was reduced 
upon depletion of SDHB or VHL, we tested whether 
inhibition of the Aurora-A/HDAC6 pathway prevented 
cilia loss. PC12 cells were transfected with siRNAs targeting 
Sdhb or Vhl and then cultured in media containing 
PHA-680632, TSA, tubacin or vehicle only as a control. 
Forty-eight hours after transfection, cells were fixed 
and cilia were immunolabeled for confocal microscopy. 
Quantification of cilia incidence and length showed that 
treatment with the Aurora-A inhibitor PHA-680632 and 
the HDAC inhibitors TSA and tubacin reduced cilia loss 
and shortening in response to pVHL and SDHB (Fig. 6A, 
B, C, D and Supplementary Fig. 6) knockdown. Inhibition 
of HIF signaling with FM19G11 also reduced cilia loss in 
both Sdhb- and Vhl-depleted cells (Fig.  6A, B, C, D and 
Supplementary Fig. 6). Together, these data indicate that 
the Aurora-A/HDAC6 pathway is a modulator of cilia loss 
in PC12 cells depleted for SDHB or pVHL.
Discussion
Data presented here are the first to show that primary 
cilia are lost from PCCs compared to normal adjacent 
adrenal medulla. This corresponds with observations 
that primary cilia structure and function is disrupted in a 
broad range of cancers (O’Toole & Chapple 2016). These 
include breast, prostate, renal, pancreatic, melanoma, 
cholangiocarcinoma, glioblastoma, chondrosarcoma and 
colon cancer (Moser et al. 2009, Schraml et al. 2009, Seeley 
et al. 2009, Yuan et al. 2010, Kim et al. 2011, Gradilone 
et al. 2013, Hassounah et al. 2013, Ho et al. 2013, Rocha 
et  al. 2014). In PCCs, the degree of cilia loss was more 
pronounced in tumors from patients with germline 
mutations in pseudohypoxia-linked genes VHL and SDHB. 
For pVHL, this may be partly explained by its reported non-
canonical function in ciliogenesis, by orienting growth 
of microtubules toward the cell periphery (Schermer 
et  al. 2006). Cilia frequency is also reduced relative to 
neighboring tissue in ccRCC. The VHL gene is inactivated 
in the majority (87%) of sporadic clear-cell RCCs (Moore 
et  al. 2011), with ccRCCs also occurring as part of 
Figure 6
Inhibition of cilia resorption and hypoxic signaling 
prevents cilia loss caused by knockdown of SDHB 
and VHL. (A and B) Quantification of primary cilia 
incidence (A) and axonemal length (B) 48 h after 
transfection with siRNAs targeting SDHB in the 
presence or absence of the inhibitors FM19G11, 
TSA, tubacin (Tub) and PHA-680632 (PHA), or 
vehicle only controls. Cells transfected with 
non-targeting control siRNAs (Con) were treated 
with the same inhibitors. (C and D) Quantification 
of primary cilia incidence (C) and axonemal length 
(D) 48 h after transfection with siRNAs targeting 
VHL in the presence or absence of the inhibitors 
used in Fig. 6A and B. Cilia scoring was performed 
in ten randomly selected fields for each 
experimental condition in three biological 
replicates. Mean axonemal length was quantified 
from at least 50 ciliated cells for each 
experimental condition. Error bars indicate 2× 
s.e.m. Box and whisker plots are as in Fig. 3. 
Statistical tests: ANOVA. *P < 0.05, **P < 0.01, 
***P < 0.001.
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von Hippel–Lindau disease (Gossage et  al. 2015, Crespigio 
et al. 2017). Contrasting ccRCC, VHL inactivation is a much 
less common feature of sporadic PCCs (Dannenberg et al. 
2003, Burnichon et al. 2011). In the context of our data, 
this suggests that although disruption of a cilia-specific 
function of VHL may contribute to loss of cilia in PCC, it 
is not the main mechanism responsible for cilia loss.
Using the PCC-derived PC12 cell line, we found that 
siRNA-mediated depletion of SDHB, FH and VHL, all 
resulted in reduction of cilia frequency. We also observed 
that treatment of cells with drugs that inhibit HIF-PHs, 
SDH and FH, leading to accumulation of oncometabolites 
for SDH and FH, caused cilia loss. Culture of PC12 cells 
in conditions of reduced oxygen similarly reduced the 
incidence of cilia, although it should be noted the change 
in oxygen concentration from 21% (standard for cell 
culture) to 1% is greater than will to occur in vivo, where 
physiological levels of oxygen range from 2 to 9% (Tiede 
et al. 2011). Together, these data implicate pseudohypoxic 
/hypoxic signaling as a regulator of cilia dynamics. This 
is further supported by the finding that inhibition of HIF 
signaling reduced cilia loss in response to hypoxia and 
inducers of pseudohypoxia and is consistent with studies 
that show axoneme length is influenced by hypoxia-
inducible mechanisms (Proulx-Bonneau & Annabi 2011, 
Wann et al. 2013). Hypoxia is not just a driver of PCC/PGL 
formation (Rodriguez-Cuevas et al. 1986, Opotowsky et al. 
2015), but is also a salient feature of many solid tumors, 
and may therefore modulate cilia presence in cancers 
more generally.
There are a number of potential pathways through 
which HIF signaling could influence ciliogenesis and 
resorption. These include that stabilization of HIF 
promotes transcription of Aurora-A kinase, which 
functions in regulation of ciliary resorption with HDAC6 
(Pugacheva et  al. 2007, Xu et  al. 2010). Inhibition of 
the Aurora-A/HDAC6 pathway in PC12 cells prevented 
cilia loss in response to hypoxia and induction of 
pseudohypoxia. Collectively, these findings suggest that 
the reduction in cilia frequency in pseudohypoxic PCC 
is likely to be mediated by both HIF signaling and the 
Aurora-A/HDAC6 cilia resorption pathway, although 
involvement of other regulators of cilia dynamics is 
also possible.
Transcriptome analyses identified altered expression 
of gene modules associated with cilia-mediated signaling 
in PCCs relative to adjacent adrenal medulla. Altered 
cilia-mediated signaling pathways included Hh, WNT 
and Notch signaling. The role of cilia in the regulation 
of cancer-linked signaling pathways is complex and 
context dependent (Oh & Katsanis 2013). For example, 
WNT signaling, which is generally considered to be 
attenuated by the presence of a cilium, can be decreased 
in cells with shortened cilia yet activated by ablation of 
cilia (Lancaster et al. 2011, Oh & Katsanis 2013), while 
for Hh signaling, the cilium activates the pathway in 
the presence of the sonic hedgehog ligand (SHH) and 
restrains signaling when SHH is absent (Wong et al. 2009, 
Hassounah et al. 2012). There is also crosstalk between 
cilia-mediated signaling pathways, such as Notch 
signaling modulating SHH signaling, by regulating the 
ciliary localization of the Hh signal transduction proteins 
patched and smoothened (Kong et  al. 2015). This 
complexity makes it difficult to interpret how alterations 
in cilia incidence and length may impact on specific 
pathways. Nevertheless, hierarchical clustering analyses 
separately grouped tumor and adrenal medulla samples 
based on changes of gene expression in multiple cilia-
linked signaling pathways. This is consistent with loss 
of cilia correlating with dysregulation of cilia-mediated 
signaling in PCCs. Disruption of WNT signaling is 
particularly relevant to PCC/PGLs, with WNT-altered 
tumors classified as one of four molecularly defined 
PCC/PGL subtypes (Fishbein et al. 2017).
In addition to modulating signaling pathways that are 
dysregulated in tumorigenesis and cancer, the presence of 
a primary cilium may act as a checkpoint for cell division. 
We observed that disruption of cilia structure and 
function, by knockdown of Ift88 or Cep164, correlated 
with increased cellular proliferation of PC12 cells. This 
was accompanied by changes in gene expression that 
inhibited cell death pathways, while activating cell 
proliferation and tumor-linked pathways. Together, our 
data are concordant with cilia acting as a checkpoint for 
cell division in PC12 cells and suggest cilia loss promotes 
proliferation and perhaps tumorigenesis in PCC/PGL. 
Interestingly, we also observed that in PCC tissue, there 
was a correlation between degree of cilia loss and Ki67 
staining implying in vivo relevance of our findings in 
PC12 cells.
In summary, we propose that in PCC/PGLs 
oncometabolite-induced pseudohypoxia drives cilia 
loss through activation of the Aurora-A kinase/HDAC6 
cilia resorption pathway. In PCCs, this cilia loss causes 
dysregulation of cilia-mediated signaling pathways 
including SHH, WNT and Notch signaling and is also 
likely to promote increased cellular proliferation (Fig. 7). 
Hypoxia-induced cilia resorption may be a feature of 
cancers more generally and represents a potential target 
to slow tumor progression.
https://doi.org/10.1530/ERC-18-0134
https://erc.bioscientifica.com © 2019 The authors
Printed in Great Britain
Published by Bioscientifica Ltd.
This work is licensed under a Creative Commons 
Attribution 4.0 International License.
Downloaded from Bioscientifica.com at 11/08/2019 12:42:39PM
via free access
178S M O’Toole et al. Cilia loss in 
pheochromocytoma
26:1Endocrine-Related 
Cancer
Supplementary data
This is linked to the online version of the paper at https://doi.org/10.1530/
ERC-18-0134.
Declaration of interest
The authors declare that there is no conflict of interest that could be 
perceived as prejudicing the impartiality of the research reported.
Funding
This work was funded by a Barts and the London Charity Clinical Research 
Training Fellowships awarded to Samuel M O’Toole (grant number 
MRD0191) and by a project grant from the UK Medical Research Council 
(MRC) (grant number MR/L002876/1). Dr Tyson V Sharp is funded by grants 
from the UK Biotechnology and Biological Sciences Research Council 
(grant number BB/M0020611) and MRC (grant number MR/N009185/1). 
The LSM880 confocal used in these studies was purchased through a 
Barts and the London Charity award (grant number MGU0293). The RNA-
Seq analyses were in part funded by a grant from The Medical College of 
Saint Bartholomew’s Hospital Trust and were performed at the Barts and 
the London Genome Centre. This work also forms part of the research 
themes contributing to the translational research portfolio of Barts and the 
London Cardiovascular Biomedical Research Centre, which is supported 
and funded by the National Institute of Health Research. This project was 
enabled through access to the MRC eMedLab Medical Bioinformatics 
infrastructure, supported by the MRC (grant number MR/L016311/1).
Author contribution statement
S M O, P J K, M M K, T V S, U S, W M D and J P C conceived and planned 
the experiments. S M O, L E L R, T V N, T Y B and C L T carried out the 
experiments. S M O, D S W, M R B and J P C analyzed and interpreted the 
data. S M O and J P C wrote the draft manuscript. All authors provided 
critical feedback, which shaped the research, analysis and the manuscript.
Acknowledgements
The authors would like to thank the following clinical colleagues for collection 
of PCC and adrenal samples: Mr Robert Carpenter and Ms Laila Parvanta (St 
Bartholomew’s Hospital, London); Mr Tom Kurzawinski and Mr Tarek Abdel-
Aziz (University College London Hospitals, London); Prof. Michael Gleeson 
(National Hospital for Neurology and Neurosurgery). They are also extremely 
grateful to the patients who donated these tissues. The MPC and MTT cell 
lines where a gift from Dr Karel Pacak (NIH), via Professor Marta Korbonits 
(Queen Mary University of London). Prof. Korbonits was also principal 
investigator for ethical approvals related to this work. They would also like 
to thank Profs. Morris Brown, Jacky Burrin and Adrian Clark (Queen Mary 
University of London) for their constructive comments on the manuscript.
References
Basten SG, Willekers S, Vermaat JS, Slaats GG, Voest EE, van Diest PJ & 
Giles RH 2013 Reduced cilia frequencies in human renal cell 
carcinomas versus neighboring parenchymal tissue. Cilia 2 2. 
(https://doi.org/10.1186/2046-2530-2-2)
Figure 7
Model illustrating the potential pathway from 
pseudohypoxia-induced cilia loss to increased cell 
proliferation and dysregulation of tumorigenesis 
relevant cilia-mediated signaling pathways in 
PCCs. Proteins where germline mutations in the 
gene predispose to PCC are in orange boxes. 
Aurora-A, Aurora-A kinase; FH, fumarate 
hydratase; H6, HDAC6; HIF, hypoxia-inducible 
factor; OH, hydroxyl group; P, phosphate group; 
PH, prolyl-hydroxylases; SDH, succinate 
dehydrogenase; VHL, von Hippel–Lindau protein.
H6
H6
H6
AuroraA
Hypoxia
Pseudohypoxia
Proteasomal
degradation
HIF1a
VHL
PHD
HIF1a
OH
OH
HIF1a HIF1b
H6
AuroraA
P
P
Succinate α-KG
n
u
c
le
u
s
Target gene transcription
FumarateMalate
O2
SDHFH
Activation of
Aurora A
Cilia loss
Dysregulation of cilia mediated 
signalling e.g. Hh, Wnt, Notch.
Increased cell prolifieration?
Inhibition of HIFα,
AuroraA or HDAC6
https://doi.org/10.1530/ERC-18-0134
https://erc.bioscientifica.com © 2019 The authors
Printed in Great Britain
Published by Bioscientifica Ltd.
This work is licensed under a Creative Commons 
Attribution 4.0 International License.
Downloaded from Bioscientifica.com at 11/08/2019 12:42:39PM
via free access
179S M O’Toole et al. Cilia loss in 
pheochromocytoma
26:1Endocrine-Related 
Cancer
Berbari NF, O’Connor AK, Haycraft CJ & Yoder BK 2009 The primary 
cilium as a complex signaling center. Current Biology 19 R526–R535. 
(https://doi.org/10.1016/j.cub.2009.05.025)
Burnichon N, Vescovo L, Amar L, Libe R, de Reynies A, Venisse A, 
Jouanno E, Laurendeau I, Parfait B, Bertherat J, et al. 2011 
Integrative genomic analysis reveals somatic mutations in 
pheochromocytoma and paraganglioma. Human Molecular Genetics 
20 3974–3985. (https://doi.org/10.1093/hmg/ddr324)
Burnichon N, Cascon A, Schiavi F, Morales NP, Comino-Mendez I, 
Abermil N, Inglada-Perez L, de Cubas AA, Amar L, Barontini M, et al. 
2012 MAX mutations cause hereditary and sporadic 
pheochromocytoma and paraganglioma. Clinical Cancer Research 18 
2828–2837. (https://doi.org/10.1158/1078-0432.CCR-12-0160)
Burnichon N, Buffet A & Gimenez-Roqueplo AP 2016 
Pheochromocytoma and paraganglioma: molecular testing and 
personalized medicine. Current Opinion in Oncology 28 5–10. (https://
doi.org/10.1097/CCO.0000000000000249)
Clarke MR, Weyant RJ, Watson CG & Carty SE 1998 Prognostic markers 
in pheochromocytoma. Human Pathology 29 522–526. (https://doi.
org/10.1016/S0046-8177(98)90070-3)
Crespigio J, Berbel LCL, Dias MA, Berbel RF, Pereira SS, Pignatelli D & 
Mazzuco TL 2017 Von Hippel-Lindau disease: a single gene, several 
hereditary tumors. Journal of Endocrinological Investigation 41 21–31. 
(https://doi.org/10.1007/s40618-017-0683-1)
Dahia PL 2017 Pheochromocytomas and paragangliomas, genetically 
diverse and minimalist, all at once! Cancer Cell 31 159–161. (https://
doi.org/10.1016/j.ccell.2017.01.009)
Dannenberg H, De Krijger RR, van der Harst E, Abbou M, Ijzendoorn Y, 
Komminoth P & Dinjens WN 2003 Von Hippel-Lindau gene alterations 
in sporadic benign and malignant pheochromocytomas. International 
Journal of Cancer 105 190–195. (https://doi.org/10.1002/ijc.11060)
Fishbein L & Nathanson KL 2012 Pheochromocytoma and 
paraganglioma: understanding the complexities of the genetic 
background. Cancer Genetics 205 1–11. (https://doi.org/10.1016/j.
cancergen.2012.01.009)
Fishbein L, Leshchiner I, Walter V, Danilova L, Robertson AG, 
Johnson AR, Lichtenberg TM, Murray BA, Ghayee HK, Else T, et al. 
2017 Comprehensive molecular characterization of 
pheochromocytoma and paraganglioma. Cancer Cell 31 181–193. 
(https://doi.org/10.1016/j.ccell.2017.01.001)
Goetz SC & Anderson KV 2010 The primary cilium: a signalling centre 
during vertebrate development. Nature Reviews Genetics 11 331–344. 
(https://doi.org/10.1038/nrg2774)
Gossage L, Eisen T & Maher ER 2015 VHL, the story of a tumour 
suppressor gene. Nature Reviews Cancer 15 55–64. (https://doi.
org/10.1038/nrc3844)
Goto H, Inoko A & Inagaki M 2013 Cell cycle progression by the 
repression of primary cilia formation in proliferating cells. Cellular 
and Molecular Life Sciences 70 3893–3905. (https://doi.org/10.1007/
s00018-013-1302-8)
Gradilone SA, Radtke BN, Bogert PS, Huang BQ, Gajdos GB & 
LaRusso NF 2013 HDAC6 inhibition restores ciliary expression and 
decreases tumor growth. Cancer Research 73 2259–2270. (https://doi.
org/10.1158/0008-5472.CAN-12-2938)
Graser S, Stierhof YD, Lavoie SB, Gassner OS, Lamla S, Le Clech M & 
Nigg EA 2007 Cep164, a novel centriole appendage protein required 
for primary cilium formation. Journal of Cell Biology 179 321–330. 
(https://doi.org/10.1083/jcb.200707181)
Hassounah NB, Bunch TA & McDermott KM 2012 Molecular pathways: 
the role of primary cilia in cancer progression and therapeutics with 
a focus on Hedgehog signaling. Clinical Cancer Research 18  
2429–2435. (https://doi.org/10.1158/1078-0432.CCR-11-0755)
Hassounah NB, Nagle R, Saboda K, Roe DJ, Dalkin BL & McDermott KM 
2013 Primary cilia are lost in preinvasive and invasive prostate 
cancer. PLoS ONE 8 e68521. (https://doi.org/10.1371/journal.
pone.0068521)
Ho L, Ali SA, Al-Jazrawe M, Kandel R, Wunder JS & Alman BA 2013 
Primary cilia attenuate hedgehog signalling in neoplastic 
chondrocytes. Oncogene 32 5388–5396. (https://doi.org/10.1038/
onc.2012.588)
Hopewell R & Ziff EB 1995 The nerve growth factor-responsive PC12 cell 
line does not express the Myc dimerization partner Max. Molecular 
and Cellular Biology 15 3470–3478. (https://doi.org/10.1128/
MCB.15.7.3470)
Huber W, Carey VJ, Gentleman R, Anders S, Carlson M, Carvalho BS, 
Bravo HC, Davis S, Gatto L, Girke T, et al. 2015 Orchestrating high-
throughput genomic analysis with bioconductor. Nature Methods 12 
115–121. (https://doi.org/10.1038/nmeth.3252)
Izawa I, Goto H, Kasahara K & Inagaki M 2015 Current topics of 
functional links between primary cilia and cell cycle. Cilia 4 12. 
(https://doi.org/10.1186/s13630-015-0021-1)
Johnson CA, Collis SJ 2016 Ciliogenesis and the DNA damage response: 
a stressful relationship. Cilia 5 19. (https://doi.org/10.1186/s13630-
016-0040-6)
Kim J, Dabiri S & Seeley ES 2011 Primary cilium depletion typifies 
cutaneous melanoma in situ and malignant melanoma. PLoS ONE 6 
e27410. (https://doi.org/10.1371/journal.pone.0027410)
Kimura N, Takayanagi R, Takizawa N, Itagaki E, Katabami T, Kakoi N, 
Rakugi H, Ikeda Y, Tanabe A, Nigawara T, et al. 2014 Pathological 
grading for predicting metastasis in phaeochromocytoma and 
paraganglioma. Endocrine-Related Cancer 21 405–414. (https://doi.
org/10.1530/ERC-13-0494)
Kong JH, Yang L, Dessaud E, Chuang K, Moore DM, Rohatgi R, Briscoe J 
& Novitch BG 2015 Notch activity modulates the responsiveness of 
neural progenitors to sonic hedgehog signaling. Developmental Cell 
33 373–387. (https://doi.org/10.1016/j.devcel.2015.03.005)
Korpershoek E, Pacak K & Martiniova L 2012 Murine models and cell 
lines for the investigation of pheochromocytoma: applications for 
future therapies? Endocrine Pathology 23 43–54. (https://doi.
org/10.1007/s12022-012-9194-y)
Lancaster MA, Schroth J & Gleeson JG 2011 Subcellular spatial 
regulation of canonical Wnt signalling at the primary cilium. Nature 
Cell Biology 13 700–707. (https://doi.org/10.1038/ncb2259)
Love MI, Huber W & Anders S 2014 Moderated estimation of fold 
change and dispersion for RNA-seq data with DESeq2. Genome 
Biology 15 550. (https://doi.org/10.1186/s13059-014-0550-8)
MacKenzie ED, Selak MA, Tennant DA, Payne LJ, Crosby S, 
Frederiksen CM, Watson DG & Gottlieb E 2007 Cell-permeating 
alpha-ketoglutarate derivatives alleviate pseudohypoxia in succinate 
dehydrogenase-deficient cells. Molecular and Cellular Biology 27  
3282–3289. (https://doi.org/10.1128/MCB.01927-06)
Mans DA, Voest EE & Giles RH 2008 All Along the Watchtower: is the 
cilium a tumor suppressor organelle? Biochimica et Biophysica Acta 
1786 114–125. (https://doi.org/10.1016/j.bbcan.2008.02.002)
Moore LE, Nickerson ML, Brennan P, Toro JR, Jaeger E, Rinsky J, Han SS, 
Zaridze D, Matveev V, Janout V, et al. 2011 Von Hippel-Lindau (VHL) 
inactivation in sporadic clear cell renal cancer: associations with 
germline VHL polymorphisms and etiologic risk factors. PLoS 
Genetics 7 e1002312. (https://doi.org/10.1371/journal.pgen.1002312)
Moreno-Manzano V, Rodriguez-Jimenez FJ, Acena-Bonilla JL, Fustero-
Lardies S, Erceg S, Dopazo J, Montaner D, Stojkovic M & Sanchez-
Puelles JM 2010 FM19G11, a new hypoxia-inducible factor (HIF) 
modulator, affects stem cell differentiation status. Journal of Biological 
Chemistry 285 1333–1342. (https://doi.org/10.1074/jbc.
M109.008326)
Moser JJ, Fritzler MJ & Rattner JB 2009 Primary ciliogenesis defects are 
associated with human astrocytoma/glioblastoma cells. BMC Cancer 
9 448. (https://doi.org/10.1186/1471-2407-9-448)
Oh EC & Katsanis N 2013 Context-dependent regulation of Wnt 
signaling through the primary cilium. Journal of the American  
Society of Nephrology 24 10–18. (https://doi.org/10.1681/
ASN.2012050526)
https://doi.org/10.1530/ERC-18-0134
https://erc.bioscientifica.com © 2019 The authors
Printed in Great Britain
Published by Bioscientifica Ltd.
This work is licensed under a Creative Commons 
Attribution 4.0 International License.
Downloaded from Bioscientifica.com at 11/08/2019 12:42:39PM
via free access
180S M O’Toole et al. Cilia loss in 
pheochromocytoma
26:1Endocrine-Related 
Cancer
Opotowsky AR, Moko LE, Ginns J, Rosenbaum M, Greutmann M, 
Aboulhosn J, Hageman A, Kim Y, Deng LX, Grewal J, et al. 2015 
Pheochromocytoma and paraganglioma in cyanotic congenital heart 
disease. Journal of Clinical Endocrinology and Metabolism 100  
1325–1334. (https://doi.org/10.1210/jc.2014-3863)
O’Toole SM & Chapple JP 2016 Primary cilia: a link between hormone 
signalling and endocrine-related cancers? Biochemical Society 
Transactions 44 1227–1234. (https://doi.org/10.1042/BST20160149)
Pazour GJ, Dickert BL, Vucica Y, Seeley ES, Rosenbaum JL, Witman GB & 
Cole DG 2000 Chlamydomonas IFT88 and its mouse homologue, 
polycystic kidney disease gene tg737, are required for assembly of 
cilia and flagella. Journal of Cell Biology 151 709–718. (https://doi.
org/10.1083/jcb.151.3.709)
Proulx-Bonneau S & Annabi B 2011 The primary cilium as a biomarker 
in the hypoxic adaptation of bone marrow-derived mesenchymal 
stromal cells: a role for the secreted frizzled-related proteins. Biomark 
Insights 6 107–118. (https://doi.org/10.4137/BMI.S8247)
Pugacheva EN, Jablonski SA, Hartman TR, Henske EP & Golemis EA 2007 
HEF1-dependent Aurora A activation induces disassembly of the primary 
cilium. Cell 129 1351–1363. (https://doi.org/10.1016/j.cell.2007.04.035)
Rocha C, Papon L, Cacheux W, Marques Sousa P, Lascano V, Tort O, 
Giordano T, Vacher S, Lemmers B, Mariani P, et al. 2014 Tubulin 
glycylases are required for primary cilia, control of cell proliferation 
and tumor development in colon. EMBO Journal 33 2247–2260. 
(https://doi.org/10.15252/embj.201488466)
Rodriguez-Cuevas H, Lau I & Rodriguez HP 1986 High-altitude 
paragangliomas diagnostic and therapeutic considerations. Cancer 57 
672–676. (https://doi.org/10.1002/1097-0142(19860201)57:3<672::AID-
CNCR2820570346>3.0.CO;2-C)
Schermer B, Ghenoiu C, Bartram M, Muller RU, Kotsis F, Hohne M, 
Kuhn W, Rapka M, Nitschke R, Zentgraf H, et al. 2006 The von 
Hippel-Lindau tumor suppressor protein controls ciliogenesis by 
orienting microtubule growth. Journal of Cell Biology 175 547–554. 
(https://doi.org/10.1083/jcb.200605092)
Schraml P, Frew IJ, Thoma CR, Boysen G, Struckmann K, Krek W & 
Moch H 2009 Sporadic clear cell renal cell carcinoma but not the 
papillary type is characterized by severely reduced frequency of 
primary cilia. Modern Pathology 22 31–36. (https://doi.org/10.1038/
modpathol.2008.132)
Seeley ES, Carriere C, Goetze T, Longnecker DS & Korc M 2009 
Pancreatic cancer and precursor pancreatic intraepithelial neoplasia 
lesions are devoid of primary cilia. Cancer Research 69 422–430. 
(https://doi.org/10.1158/0008-5472.CAN-08-1290)
Selak MA, Armour SM, MacKenzie ED, Boulahbel H, Watson DG, 
Mansfield KD, Pan Y, Simon MC, Thompson CB & Gottlieb E 2005 
Succinate links TCA cycle dysfunction to oncogenesis by inhibiting 
HIF-alpha prolyl hydroxylase. Cancer Cell 7 77–85. (https://doi.
org/10.1016/j.ccr.2004.11.022)
Thoma CR, Frew IJ, Hoerner CR, Montani M, Moch H & Krek W 2007 
pVHL and GSK3beta are components of a primary cilium-
maintenance signalling network. Nature Cell Biology 9 588–595. 
(https://doi.org/10.1038/ncb1579)
Tiede LM, Cook EA, Morsey B & Fox HS 2011 Oxygen matters: tissue 
culture oxygen levels affect mitochondrial function and structure as 
well as responses to HIV viroproteins. Cell Death and Disease 2 e246. 
(https://doi.org/10.1038/cddis.2011.128)
Wann AK, Thompson CL, Chapple JP & Knight MM 2013 Interleukin-
1beta sequesters hypoxia inducible factor 2alpha to the primary 
cilium. Cilia 2 17. (https://doi.org/10.1186/2046-2530-2-17)
Wong SY, Seol AD, So PL, Ermilov AN, Bichakjian CK, Epstein EH, Jr., 
Dlugosz AA & Reiter JF 2009 Primary cilia can both mediate and 
suppress Hedgehog pathway-dependent tumorigenesis. Nature 
Medicine 15 1055–1061. (https://doi.org/10.1038/nm.2011)
Xu J, Li H, Wang B, Xu Y, Yang J, Zhang X, Harten SK, Shukla D, 
Maxwell PH, Pei D, et al. 2010 VHL inactivation induces HEF1 and 
Aurora kinase A. Journal of the American Society of Nephrology 21 
2041–2046. (https://doi.org/10.1681/ASN.2010040345)
Yuan K, Frolova N, Xie Y, Wang D, Cook L, Kwon YJ, Steg AD, Serra R 
& Frost AR 2010 Primary cilia are decreased in breast cancer: 
analysis of a collection of human breast cancer cell lines and 
tissues. Journal of Histochemistry and Cytochemistry 58 857–870. 
(https://doi.org/10.1369/jhc.2010.955856)
Received in final form 27 August 2018
Accepted 5 September 2018
Accepted Preprint published online 7 September 2018
https://doi.org/10.1530/ERC-18-0134
https://erc.bioscientifica.com © 2019 The authors
Printed in Great Britain
Published by Bioscientifica Ltd.
This work is licensed under a Creative Commons 
Attribution 4.0 International License.
Downloaded from Bioscientifica.com at 11/08/2019 12:42:39PM
via free access
